Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 81Carcinoma, Non-Small-Cell Lung 41Colonic Neoplasms 40Lung Neoplasms 39Leukemia 36Rectal Neoplasms 34Lymphoma 34Colorectal Neoplasms 33Prostatic Neoplasms 24Multiple Myeloma 23Lymphoma, Follicular 22Leukemia, Myeloid, Acute 19Ovarian Neoplasms 18Lymphoma, Non-Hodgkin 18Leukemia, Lymphocytic, Chronic, B-Cell 18Lymphoma, Large B-Cell, Diffuse 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Melanoma 16Head and Neck Neoplasms 15Urinary Bladder Neoplasms 14Neoplasms, Plasma Cell 14Lymphoma, Large-Cell, Immunoblastic 14Burkitt Lymphoma 14Squamous Cell Carcinoma of Head and Neck 12Pancreatic Neoplasms 12Myelodysplastic Syndromes 12Leukemia, Myelomonocytic, Acute 12Leukemia, Monocytic, Acute 12Leukemia, Megakaryoblastic, Acute 12Leukemia, Erythroblastic, Acute 12

Interventions

prednylidene 1etoposide phosphate 1deltacortene 1Vincristine 1Vinblastine 1Specimen Handling 1Procarbazine 1Prednisone 1Prednisolone 1Nivolumab 1Methylprednisolone 1Magnetic Resonance Spectroscopy 1Fluorodeoxyglucose F18 1Etoposide 1Doxorubicin 1Dacarbazine 1Cyclophosphamide 1Brentuximab Vedotin 1Bleomycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × NIH × Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 × Clear all
NCT05675410 2026-06-03

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

National Cancer Institute (NCI)

Phase 3 Recruiting
1,875 enrolled
Lymphoid

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡